All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN previous systemic treatment (%) previous systemic treatment NO (%) stage M0/M1A/M1B stage M1C stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mML - L2 - all population, ipilimumab alone vs. Immunostimulant, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results MDX010 Ipi vs gp100, 2010 0.66 [0.51; 0.86]
0.66 [0.51 ; 0.86 ] MDX010 Ipi vs gp100, 2010 1 0% 273 NA not evaluable objective responses (ORR)detailed results MDX010 Ipi vs gp100, 2010 8.24 [1.85; 36.76]
8.24 [1.85 ; 36.76 ] MDX010 Ipi vs gp100, 2010 1 0% 273 NA not evaluable AE (any grade)detailed results MDX010 Ipi vs gp100, 2010 0.99 [0.24; 4.05]
0.99 [0.24 ; 4.05 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable AE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 0.95 [0.59; 1.55]
0.95 [0.59 ; 1.55 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable TRAE (any grade)detailed results MDX010 Ipi vs gp100, 2010 1.09 [0.60; 1.98]
1.09 [0.60 ; 1.98 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable TRAE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 1.41 [0.69; 2.88]
1.41 [0.69 ; 2.88 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
1.01 [0.02 ; 51.17 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Colitis TRAE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 14.85 [0.83; 264.38]
14.85 [0.83 ; 264.38 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 6.29 [0.75; 52.98]
6.29 [0.75 ; 52.98 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results MDX010 Ipi vs gp100, 2010 10.44 [0.56; 193.00]
10.44 [0.56 ; 193.00 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results MDX010 Ipi vs gp100, 2010 10.83 [1.37; 85.84]
10.83 [1.37 ; 85.84 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
1.01 [0.02 ; 51.17 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results MDX010 Ipi vs gp100, 2010 0.16 [0.01; 3.32]
0.16 [0.01 ; 3.32 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 4.08 [0.18; 91.29]
4.08 [0.18 ; 91.29 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
1.01 [0.02 ; 51.17 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Increase AST TRAE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
1.01 [0.02 ; 51.17 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
1.01 [0.02 ; 51.17 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Pruritus TRAE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
1.01 [0.02 ; 51.17 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Rash TRAE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 2.02 [0.07; 60.83]
2.02 [0.07 ; 60.83 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results MDX010 Ipi vs gp100, 2010 4.08 [0.18; 91.29]
4.08 [0.18 ; 91.29 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Vitiligo TRAE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
1.01 [0.02 ; 51.17 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Abdominal pain AE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 0.28 [0.06; 1.36]
0.28 [0.06 ; 1.36 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Anaemia AE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 0.35 [0.11; 1.12]
0.35 [0.11 ; 1.12 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Constipation AE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 3.07 [0.32; 29.91]
3.07 [0.32 ; 29.91 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Cough AE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
1.01 [0.02 ; 51.17 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Decreased appetite AE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 0.50 [0.09; 2.76]
0.50 [0.09 ; 2.76 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Diarrhoea AE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 7.40 [0.90; 60.98]
7.40 [0.90 ; 60.98 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Dyspnoea AE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 0.83 [0.25; 2.80]
0.83 [0.25 ; 2.80 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Fatigue AE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 2.36 [0.71; 7.87]
2.36 [0.71 ; 7.87 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Headache AE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 1.01 [0.20; 5.09]
1.01 [0.20 ; 5.09 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Nausea AE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 1.01 [0.20; 5.09]
1.01 [0.20 ; 5.09 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Pyrexia AE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 0.25 [0.01; 5.58]
0.25 [0.01 ; 5.58 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable Vomiting AE (grade 3-4)detailed results MDX010 Ipi vs gp100, 2010 1.01 [0.20; 5.09]
1.01 [0.20 ; 5.09 ] MDX010 Ipi vs gp100, 2010 1 0% 263 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-03 09:32 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 69
- treatments: 329,558